Spero Therapeutics, Inc.
SPRO
$1.17
-$0.02-1.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -99.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -99.38% | |||
| Cost of Revenue | 18.05% | 110.66% | |||
| Gross Profit | -29.54% | -102.41% | |||
| SG&A Expenses | 32.84% | 13.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.32% | -21.19% | |||
| Operating Income | -31.68% | -124.00% | |||
| Income Before Tax | -32.61% | -122.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -32.61% | -122.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.61% | -122.85% | |||
| EBIT | -31.68% | -124.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -31.11% | -122.34% | |||
| Normalized Basic EPS | -31.04% | -122.17% | |||
| EPS Diluted | -31.11% | -123.46% | |||
| Normalized Diluted EPS | -31.04% | -123.49% | |||
| Average Basic Shares Outstanding | 1.20% | 2.25% | |||
| Average Diluted Shares Outstanding | 1.20% | -3.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||